Severe Hyperkalemia in Advanced CKD and Heart Failure
A 71-year-old woman with heart failure with reduced ejection fraction (EF 30%) and stage 4 chronic kidney disease (baseline creatinine 2.6 mg/dL, eGFR 22 mL/min/1.73 m²) presents with 3 days of nausea, poor oral intake, and generalized weakness. Medications are sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily, and metoprolol succinate 50 mg daily. Blood pressure is 106/62 mmHg, heart rate 52 beats/min, and oxygen saturation 96% on room air. She is drowsy but oriented. ECG shows peaked T waves, a PR interval of 0.24 seconds, and a QRS duration of 0.12 seconds. Potassium is 6.7 mEq/L, bicarbonate 19 mEq/L, creatinine 3.4 mg/dL, blood urea nitrogen 62 mg/dL, glucose 118 mg/dL, and calcium 8.4 mg/dL. There is no access to urgent dialysis overnight at this hospital.
1. What is your immediate management sequence for this hyperkalemia, and why is each step ordered that way?
Read the worked answer
The ECG changes-peaked T waves, PR prolongation, and QRS widening-make this severe hyperkalemia with cardiac membrane instability. Order matters. First give intravenous calcium gluconate 10% 10–30 mL (or calcium chloride) to stabilize the myocardium; it does not lower potassium but acts within minutes, and it should not be withheld while waiting for repeat labs. Repeat the calcium if the ECG does not improve. Second, shift potassium intracellularly: regular insulin 10 units IV with 25 g dextrose (50 mL of D50W), and nebulized albuterol 10–20 mg as an adjunct. Because she has CKD, insulin clearance is reduced, so monitor glucose for at least 6 hours and use a lower insulin dose if hypoglycemia risk is high. Third, remove potassium: stop spironolactone, sacubitril/valsartan, and any potassium supplements; give IV furosemide 40–80 mg if she is not volume-depleted; add a potassium binder such as sodium zirconium cyclosilicate or patiromer. Sodium bicarbonate has a slow and unreliable effect and is reserved for significant metabolic acidosis.
Recheck potassium and glucose in 1–2 hours. Arrange urgent nephrology evaluation; if potassium remains refractory, she needs dialysis.
2. Which of her heart failure medications would you stop, which would you restart, and how would you preserve guideline-directed therapy?
Read the worked answer
Spironolactone is the most likely contributor and should be held. Sacubitril/valsartan also raises potassium and should be held during the acute episode. Metoprolol does not raise potassium but may contribute to bradycardia; continue it cautiously and review the dose if heart rate remains low. Do not simply discontinue all guideline-directed therapy permanently-that would trade a reversible electrolyte problem for worse heart failure outcomes.
After potassium is below 5.0 mEq/L and renal function has stabilized, restart sacubitril/valsartan at a lower dose and recheck potassium and creatinine within 1–2 weeks. Restart spironolactone at 12.5 mg daily only if potassium is <5.0 and eGFR is >30, with close follow-up; if hyperkalemia recurs, use a potassium binder to enable it rather than abandoning it. Add an SGLT2 inhibitor such as dapagliflozin, which is indicated for HFrEF and CKD and reduces hyperkalemia risk. Avoid NSAIDs, trimethoprim, and potassium-containing salt substitutes, and provide diet counseling. The goal is to preserve neurohormonal blockade while controlling potassium.
3. Repeat potassium is 5.8 mEq/L after initial treatment and the ECG has normalized. What next, and when would you refer for dialysis?
Read the worked answer
A potassium of 5.8 mEq/L after initial treatment is still dangerous, especially after recent ECG changes. Do not discharge or simply observe. Repeat the ECG, potassium, and glucose; continue potassium removal with furosemide and a binder, treat the acute kidney injury (assess volume status, hold nephrotoxins), and correct acidosis if present. Insulin–dextrose causes a rebound rise after its effect wanes, so monitor for at least 4–6 hours. Involve nephrology early.
Refer for urgent dialysis if hyperkalemia is refractory to medical therapy, if ECG changes persist or recur, or if there is severe AKI with uremic complications, refractory volume overload, or severe acidosis. Because this hospital has no overnight dialysis, she may need transfer. Dialysis criteria are not based on potassium alone; the clinical context-AKI stage, volume status, and acid–base status-matters. Document a clear escalation plan and avoid medications that impair potassium excretion.